Myasthenia Gravis Exacerbation Following Second Dose of mRNA-1273 Vaccine

Authors

  • Urvi G. Desai M.B.B.S., M.S., M.D. Carolinas Neuromuscular MDA Care CenterAtrium Health Neurosciences Institute

DOI:

https://doi.org/10.17161/rrnmf.v2i2.15342

Keywords:

Myasthania Gravis Exacerbation, m-RNA 1273, COVID 19 Vaccinations

Abstract

NA

Metrics

Metrics Loading ...

Downloads

Download data is not yet available.

References

Guidon, A.C. and A.A. Amato, COVID-19 and neuromuscular disorders. Neurology,

94(22): p. 959-969. doi: 10.1212/WNL.0000000000009566

Paliwal, V.K., et al., Neuromuscular presentations in patients with COVID-19. Neurol Sci,

41(11): p. 3039-3056. doi: 10.1007/s10072-020-04708-8

Muppidi, S., et al., COVID-19-associated risks and effects in myasthenia gravis (CARE MG). Lancet Neurol, 2020. 19(12): p. 970-971. doi: 10.1016/S1474-4422(20)30413-0

Baden, L.R., et al., Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med, 2021. 384(5): p. 403-416. doi: 10.1056/NEJMoa2035389

Anderson, E.J., et al., Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med, 2020. 383(25): p. 2427-2438. doi: 10.1056/NEJMoa2028436

Repajic, M., et al., Bell's Palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell's palsy. Brain Behav Immun Health, 2021. 13: p. 100217. doi: 10.1016/j.bbih.2021.100217

Supplemental References :

US Food and Drug Administration (2020) Pfizer-BioNTech COVID-19 vaccine emergency use authorization review memorandum. https://www.fda.gov/media/144416/download. Accessed 15 Jan 2021

US Food and Drug Administration (2020) Moderna COVID-19 vaccine emergency use authorization review memorandum. https://www.fda.gov/media/144673/download. Accessed 15 Jan 2021

US Food and Drug Administration (2021) Janssen COVID-19 Vaccine EUA Letter of Authorization (fda.gov)

Downloads

Published

2021-05-27

Issue

Section

Clinic and Case Reports

How to Cite

Desai, U. G. (2021). Myasthenia Gravis Exacerbation Following Second Dose of mRNA-1273 Vaccine. RRNMF Neuromuscular Journal, 2(2), 46-47. https://doi.org/10.17161/rrnmf.v2i2.15342